Grace Therapeutics, Inc. (NASDAQ:GRCE)
| Market Cap | 36.13M-31.1% |
| Revenue (ttm) | 0 |
| Net Income | -21.45M-80.8% |
| EPS | -1.26-30.1% |
| Shares Out | 16.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 715,952 |
| Open | 2.29 |
| Previous Close | 2.26 |
| Day's Range | 2.20 - 2.46 |
| 52-Week Range | 1.79 - 5.18 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 4.00(+80.18%) |
| Earnings Date | Nov 12, 2026 |
About GRCE
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$GRCE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GRCE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GRCE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GRCE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New GRCE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GRCE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GRCE
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $832.73K |
| IWCiShares Micro-Cap ETF | $74.80K |
Estimated from each fund’s disclosed top holdings × AUM
GRCE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GRCE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score